Actionable news
All posts from Actionable news
Actionable news in IMGN: ImmunoGen, Inc.,


(a) Not applicable.

(b) (d) On April1, 2016, Mr.Daniel M. Junius, President and Chief Executive Officer of ImmunoGen,Inc. (also referred to as we, our, us or ImmunoGen) notified our Board of Directors of his decision to retire, effective upon the start of employment of his successor. In September2015, Mr.Junius discussed with our Board that he was considering retiring by the end of our current fiscal year if a successor could be found within that timeframe. Our Board then formed a search committee, retained an outside executive recruitment firm, and began formal succession planning. It is currently anticipated that a successor to Mr.Junius will be announced shortly. Following his retirement, Mr.Junius will continue to serve on our Board.

(e) In conne ction with Mr.Juniuss retirement, our Board of Directors has voted to:

provide that Mr.Juniuss annual cash bonus for the fiscal year ending June30, 2016 will be determined as if Mr.Junius had remained a full-time employee of ImmunoGen for the entire fiscal year and to the date such bonus is paid, regardless of his actual retirement date.

pay Mr.Junius a taxable amount on a monthly basis for up to eighteen months equal to his COBRA premium if he elects to receive COBRA benefits, and

modify the terms of certain of Mr.Juniuss stock options covering an aggregate of 1,619,854 shares, to the extent necessary to provide that (i)such stock options, to the extent currently unvested, will continue to vest in accordance with their original vesting schedules as long as Mr.Junius remains a member of our Board of Directors and (ii)all of such vested stock options (including those that will vest in the future as described above) will generally be exercisable until the earliest of (A)their original expiration date (


, ten years from the date of grant), (B)the expiration of the period of time following cessation of service for cause or by reason of his death or disability, if applicable, currently set forth in his stock option agreements (which provisions remain unchanged) or (C)one year after Mr.Junius ceases to be a director of ImmunoGen for any reason other than for cause. In the event of clause (C), Mr.Juniuss stock options shall be exercisable to the extent that they have become exercisable but not been exercised as of date of his cessation of service.

provide that Mr.Junius will become eligible to receive compensation under our Compensation Policy for Non-Employee Directors commencing the later of (i)July1, 2016 or (ii)his retirement date. A copy of this policy was filed with the Securities and Exchange Commission (SEC) on February5, 2014 as Exhibit10.3


to our quarterly report on Form10-Q for the fiscal quarter ended December31, 2013, and is incorporated herein by reference.

(f) Not applicable.



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



/s/ David B. Johnston

David B. Johnston

Executive Vice President and Chief Financial Officer


makes a similar move, sign up!

Other recent filings from the company include the following:

ImmunoGen director was just granted 1,379 restricted shares - April 4, 2016
ImmunoGen director was just granted 475 restricted shares - April 4, 2016
ImmunoGen director was just granted 1,584 restricted shares - April 4, 2016